HSD3B1 and prostate carcinoma: Prostate cancer deaths were significantly higher in patients with the HSD3B1 CC genotype (14 of 402 patients [3.5%]) compared with the HSD3B1 AC (33 of 1970 patients [1.7%]) and AA genotypes (44 of 2915 participants [1.5%]).